Chronological age represents the single greatest risk factor for human disease. One
plausible explanation for this correlation is that mechanisms that drive ageing might also …

Dual-targeting/Multi-targeting of oncoproteins by a single drug molecule represents an
efficient, logical and alternative approach to drug combinations. An increasing interest in this …

Bromodomain and extra terminal protein (BET) inhibitors are first-in-class targeted therapies
that deliver a new therapeutic opportunity by directly targeting bromodomain proteins that …

Resistance to cancer therapies presents a significant clinical challenge. Recent studies
have revealed intratumoral heterogeneity as a source of therapeutic resistance. However, it …

A detailed understanding of the mechanisms by which tumors acquire resistance to targeted
anticancer agents should speed the development of treatment strategies with lasting clinical …

Pulmonary arterial hypertension (PAH) is a life-threatening disease that can be induced by
dasatinib, a dual Src and BCR-ABL tyrosine kinase inhibitor that is used to treat chronic …

Curcumin (diferuloylmethane), the yellow pigment in Indian saffron (Curcuma longa; also
called turmeric, haldi, or haridara in the East and curry powder in the West), has been …

Chronic myeloid leukemia (CML) has been regarded as the paradigmatic example of a
malignancy defined by a unique molecular event, the BCR-ABL1 oncogene. Decades of …

Abstract Bosutinib, a dual Src/Abl kinase inhibitor, has shown potent activity against chronic
myeloid leukemia (CML). In this phase 1/2 study we evaluated bosutinib in patients with …

We describe a chemical proteomics approach to profile the interaction of small molecules
with hundreds of endogenously expressed protein kinases and purine-binding proteins. This …